Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients*

Georgios Bristoyiannis,Nikolaos Germanos,Dimitrios Grekas,Christos Hatzidimitriou,Christos Iatrou,Dimitrios Memmos,Spiros Moutafis,Konstantinos Papachristoforou,Antonis Papadoniou,Michalis Pappas,G. Sakellariou,Kostas C. Siamopoulos,Konstantinos Sombolos,Kiriaki Stamatelou,Charalambos P. Stathakis,Georgios Stavgiannoudakis,Spiros Stratigis,Christos Syrganis,Dimitris Tsakiris,Dimitris Valis,Jannis G. Vlahojannis,Dimosthenis Vlassopoulos

Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients*

2005

Background: Darbepoetin alfa is an erythropoietis-stimulating glycoprotein with a ∼3-fold longer t1/2 and greater biological activity compared with recombinant human erythropoietin (rHuEPO).

Keywords:

Erythropoietin
Anesthesia
Darbepoetin alfa
Dialysis
Dosing
Gastroenterology
Anemia
Nephropathy
Kidney disease
Tolerability
Surgery
Internal medicine
Medicine
end stage renal disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations